Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-14), Fortrea Holdings's 14-Day RSI is 61.98.
The industry rank for Fortrea Holdings's 14-Day RSI or its related term are showing as below:
FTRE's 14-Day RSI is ranked worse than 90.15% of 1422
companies
in the Biotechnology industry
Industry Median: 47.315
vs FTRE: 61.98
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Fortrea Holdings 14-Day RSI Related Terms
FTRE vs SEPN, MLTX, URGN: 14-Day RSI Comparison
For the Biotechnology subindustry, Fortrea Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (FTRE) has a 14-Day RSI of 61.98 as of Jul. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fortrea Holdings and its competitors. According to the industry distribution chart, Fortrea Holdings ranks #1282 out of 1422 companies in the Biotechnology industry, placing it in the top 90.2%.
Is Fortrea Holdings' 14-Day RSI too high?
Fortrea Holdings' current 14-Day RSI is 61.98. The Biotechnology industry median 14-Day RSI is 47.32. Fortrea Holdings' value of 61.98 is 31% above this industry median. Based on the distribution chart, Fortrea Holdings ranks #1282 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fortrea Holdings has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' 14-Day RSI compare to SEPN and MLTX?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #1282 out of 1422 companies for 14-Day RSI. This places Fortrea Holdings in the lower half of its industry. The industry median 14-Day RSI is 47.32. Fortrea Holdings' value of 61.98 is 31% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.32, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortrea Holdings's current 14-Day RSI of 61.98 is 31% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fortrea Holdings and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortrea Holdings's current 14-Day RSI is 61.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Fairly Valued. The stock's GF Value™ is $18.21, compared to a current price of $18.03 — trading 1% below its estimated fair value. The current 14-Day RSI is 61.98 and 31% above the Biotechnology industry median of 47.32. Fortrea Holdings' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current 14-Day RSI is 61.98 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FTRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued.
The current stock price of $18.03 is trading 1% below its estimated GF Value™ of $18.21.
GuruFocus considers Fortrea Holdings to be Fairly Valued.
Key valuation signals for FTRE:
14-Day RSI: 61.98
GF Value™: $18.21 vs. price of $18.03 (1% below fair value)
Industry Position: 31% above the Biotechnology median (#1282 of 1422)
No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
64GF Score
Get the complete analysis for FTRE
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FTRE has been successfully added to your 
